• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非诺贝特与血脂康对高脂饮食诱导的非酒精性脂肪性肝病的影响。

Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.

作者信息

Hong Xue Zhi, Li Lian Da, Wu Li Mao

机构信息

Institute of Chinese Herb Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, PR China.

出版信息

Clin Exp Pharmacol Physiol. 2007 Jan-Feb;34(1-2):27-35. doi: 10.1111/j.1440-1681.2007.04547.x.

DOI:10.1111/j.1440-1681.2007.04547.x
PMID:17201732
Abstract
  1. Fenofibrate and xuezhikang are two types of drugs widely used in the treatment of dyslipidaemia in China. The main purpose of present study was to test the efficacies and explore the potential mechanisms of action of the two lipid-lowering agents on high-fat diet-induced non-alcoholic fatty liver disease (NAFLD). 2. Rats were randomly divided into four groups, with eight rats per group. One group was given normal diet, whereas the other three groups were fed a high-fat diet. Forty-two days later, two of the high-fat diet-fed groups were administered fenofibrate (100 mg/kg, p.o.) and xuezhikang (300 mg/kg, p.o.) for another 42 consecutive days. The other two groups were administered placebo (saline) by gavage. 3. Typical pathological symptoms of NAFLD occurred in the high-fat diet groups. Fenofibrate and xuezhikang treatment markedly improved NAFLD, ameliorating dyslipidaemia and fat accumulation in the liver, improving insulin resistance and ameliorating oxidative stress. Hepatic steatosis, necro-inflammation and collagen deposition were lessened in the drug-treated groups. However, both xuezhikang and fenofibrate failed to reverse hepatomegaly and fenofibrate even aggravated it. Xuezhikang reversed aminotransferase abnormalities, but fenofibrate had less of an effect. 4. The common therapeutic mechanism of action of fenofibate and xuezhikang likely involves inhibition of the hepatic expression of tumour necrosis factor-alpha. Fenofibrate upregulated mRNA levels of peroxisome proliferator-activated receptor (PPAR) alpha in the liver, whereas xuezhikang had no effect on the hepatic expression of PPARalpha and this may explain, in part, their different effects on the NAFLD rats. 5. The results suggest that fenofibrate and xuezhikang may have potential clinical application in the treatment of NAFLD. However, the side-effects of fenofibrate and the underlying constituents of xuezhikang need to be determined and investigated further.
摘要
  1. 非诺贝特和血脂康是中国广泛用于治疗血脂异常的两类药物。本研究的主要目的是测试这两种降脂药物对高脂饮食诱导的非酒精性脂肪性肝病(NAFLD)的疗效,并探索其潜在作用机制。2. 将大鼠随机分为四组,每组8只。一组给予正常饮食,而其他三组给予高脂饮食。42天后,高脂饮食组中的两组分别连续42天给予非诺贝特(100mg/kg,口服)和血脂康(300mg/kg,口服)。另外两组通过灌胃给予安慰剂(生理盐水)。3. 高脂饮食组出现了NAFLD的典型病理症状。非诺贝特和血脂康治疗显著改善了NAFLD,改善了血脂异常和肝脏脂肪堆积,改善了胰岛素抵抗并减轻了氧化应激。药物治疗组的肝脂肪变性、坏死性炎症和胶原沉积减少。然而,血脂康和非诺贝特均未能逆转肝肿大,非诺贝特甚至使其加重。血脂康逆转了转氨酶异常,但非诺贝特的作用较小。4. 非诺贝特和血脂康的共同治疗作用机制可能涉及抑制肝脏肿瘤坏死因子-α的表达。非诺贝特上调了肝脏中过氧化物酶体增殖物激活受体(PPAR)α的mRNA水平,而血脂康对肝脏PPARα的表达没有影响,这可能部分解释了它们对NAFLD大鼠的不同作用。5. 结果表明,非诺贝特和血脂康在NAFLD治疗中可能具有潜在的临床应用价值。然而,非诺贝特的副作用以及血脂康的潜在成分需要进一步确定和研究。

相似文献

1
Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.非诺贝特与血脂康对高脂饮食诱导的非酒精性脂肪性肝病的影响。
Clin Exp Pharmacol Physiol. 2007 Jan-Feb;34(1-2):27-35. doi: 10.1111/j.1440-1681.2007.04547.x.
2
Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease.泽泻提取物对实验性非酒精性脂肪性肝病的保护作用。
J Pharm Pharmacol. 2006 Oct;58(10):1391-8. doi: 10.1211/jpp.57.10.0013.
3
Preventive effects of total flavonoids of Litsea coreana leve on hepatic steatosis in rats fed with high fat diet.朝鲜木姜子总黄酮对高脂饮食喂养大鼠肝脂肪变性的预防作用。
J Ethnopharmacol. 2009 Jan 12;121(1):54-60. doi: 10.1016/j.jep.2008.09.029. Epub 2008 Oct 8.
4
Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats.绞股蓝总皂苷对高脂高胆固醇饮食和酒精诱导的大鼠脂肪肝的保护作用。
Arch Pharm Res. 2012 Jul;35(7):1241-50. doi: 10.1007/s12272-012-0715-5. Epub 2012 Aug 3.
5
[Effect of peroxisome proliferator-activated receptor-alpha agonist on adipokines expression in rats fed with high-fat diet].[过氧化物酶体增殖物激活受体-α激动剂对高脂饮食喂养大鼠脂肪因子表达的影响]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006 Dec;28(6):761-5.
6
[Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity].非诺贝特对肝脏和骨骼肌中肉碱棕榈酰转移酶1基因表达的影响及其对胰岛素敏感性的影响
Zhonghua Yi Xue Za Zhi. 2008 Jan 22;88(4):268-70.
7
Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.非诺贝特是一种过氧化物酶体增殖物激活受体α激动剂,可减轻遗传性脂肪肝的Shionogi小鼠的肝脏脂肪变性和脂质过氧化。
Liver Int. 2006 Jun;26(5):613-20. doi: 10.1111/j.1478-3231.2006.01265.x.
8
[Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats].芍药总苷对增强大鼠胰岛素敏感性及拮抗非酒精性脂肪肝的作用
Zhongguo Zhong Yao Za Zhi. 2008 Oct;33(20):2385-90.
9
Preventive role of genistein in an experimental non-alcoholic steatohepatitis model.染料木黄酮在实验性非酒精性脂肪性肝炎模型中的预防作用。
J Gastroenterol Hepatol. 2007 Nov;22(11):2009-14. doi: 10.1111/j.1440-1746.2006.04681.x.
10
Triterpenoid-rich fraction from Ilex hainanensis Merr. attenuates non-alcoholic fatty liver disease induced by high fat diet in rats.从海南冬青中提取的三萜类化合物富分组分可减轻高脂肪饮食诱导的大鼠非酒精性脂肪肝病。
Am J Chin Med. 2013;41(3):487-502. doi: 10.1142/S0192415X13500353.

引用本文的文献

1
Therapeutic potential of L. extract and atorvastatin in HFD-induced MAFLD: in vitro and in vivo exploration.L提取物和阿托伐他汀在高脂饮食诱导的MAFLD中的治疗潜力:体内外研究
3 Biotech. 2025 Jun;15(6):155. doi: 10.1007/s13205-025-04322-5. Epub 2025 May 6.
2
A systematic, updated review of Xuezhikang, a domestically developed lipid-lowering drug, in the application of cardiovascular diseases.对国产降脂药物血脂康在心血管疾病应用方面的系统、最新综述。
Acta Pharm Sin B. 2024 Oct;14(10):4228-4242. doi: 10.1016/j.apsb.2024.05.011. Epub 2024 May 11.
3
The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease.
肿瘤坏死因子-α在非酒精性脂肪性肝病发病机制和治疗中的作用。
Curr Obes Rep. 2023 Sep;12(3):191-206. doi: 10.1007/s13679-023-00519-y. Epub 2023 Jul 5.
4
Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models.非诺贝特在非酒精性脂肪性肝炎/非酒精性脂肪性肝病动物模型中的肝脏保护作用。
PPAR Res. 2022 Jun 17;2022:5805398. doi: 10.1155/2022/5805398. eCollection 2022.
5
Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis.基于生物信息学分析探讨姜黄素对非酒精性脂肪性肝病中蛋白质靶标的作用。
Nutrients. 2022 Mar 22;14(7):1331. doi: 10.3390/nu14071331.
6
Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease.载脂蛋白A1在非酒精性脂肪性肝病的过氧化物酶体增殖物激活受体信号通路中的作用
PPAR Res. 2022 Feb 18;2022:4709300. doi: 10.1155/2022/4709300. eCollection 2022.
7
Is there a role of lipid-lowering therapies in the management of fatty liver disease?降脂治疗在脂肪肝疾病管理中是否发挥作用?
World J Hepatol. 2022 Jan 27;14(1):119-139. doi: 10.4254/wjh.v14.i1.119.
8
The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD.氧化应激和核受体在非酒精性脂肪性肝病发生发展中的作用及机制
Oxid Med Cell Longev. 2021 Oct 27;2021:6889533. doi: 10.1155/2021/6889533. eCollection 2021.
9
Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.草药医学治疗非酒精性脂肪性肝病——疗效、作用机制及临床应用
Front Pharmacol. 2020 May 12;11:601. doi: 10.3389/fphar.2020.00601. eCollection 2020.
10
Red Yeast Rice: A Systematic Review of the Traditional Uses, Chemistry, Pharmacology, and Quality Control of an Important Chinese Folk Medicine.红曲米:一种重要的中国民间药物传统用途、化学、药理学及质量控制的系统评价
Front Pharmacol. 2019 Dec 2;10:1449. doi: 10.3389/fphar.2019.01449. eCollection 2019.